Suven Life Sciences, a biopharmaceutical company, witnessed a rise in share price on Monday after it announced the grant of one product patent from Eurasia (020506) and one product patent from Israel (220229) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 and 2030 respectively.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

Shares of the company are trading at Rs 237.65, up Rs 4.15, or 1.78% at the Bombay Stock Exchange (BSE) on Monday at 11:47 a.m.

The scrip has touched an intra-day high of Rs 244.75 and low of Rs 230. The total volume of shares traded at the BSE is 138,345.